Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 3/20 | 0.34 |
| ▸ | LATS1 | O95835 | 1/20 | 0.31 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30248973 | 0.91 | NPBWR1 (0.35) | NPBWR1EGFRLATS1LATS2AOC3 | |
| SCHEMBL24573626 | 0.91 | NPBWR1 (0.35) | NPBWR1EGFRLATS1LATS2AOC3 | |
| SCHEMBL30248863 | 0.90 | NPBWR1 (0.34) | NPBWR1EGFRAOC3 | |
| SCHEMBL24573139 | 0.90 | NPBWR1 (0.34) | NPBWR1EGFRAOC3 | |
| SCHEMBL24573645 | 0.88 | NPBWR1 (0.33) | NPBWR1EGFR | |
| SCHEMBL29735075 | 0.88 | NPBWR1 (0.33) | NPBWR1EGFR | |
| SCHEMBL24572771 | 0.88 | EGFR (0.33) | NPBWR1EGFR | |
| SCHEMBL29735186 | 0.87 | NPBWR1 (0.33) | NPBWR1 | |
| SCHEMBL24573637 | 0.87 | NPBWR1 (0.33) | NPBWR1 | |
| SCHEMBL24573579 | 0.85 | AOC3 (0.34) | NPBWR1EGFRAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116635382-A | Indole derivatives useful for treating cGAS-related disorders | 诺华股份有限公司 | 2023-08-22 | — | — | CN | claimed |
| US-12404261-B2 | Compounds and compositions for treating conditions associated with cGAS | NOVARTIS AG (CH) | 2025-09-02 | — | — | US | disclosed |
| CN-116635382-A | Indole derivatives useful for treating cGAS-related disorders | 诺华股份有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20230085472-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH cGAS | NOVARTIS PHARMA AG (CH) | 2023-03-16 | — | — | US | disclosed |
| WO-2022137085-A1 | INDOLE DERIVATIVES USEFUL IN TREATING CONDITIONS ASSOCIATED WITH CGAS | NOVARTIS AG (CH) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404261-B2 | Compounds and compositions for treating conditions associated with cGAS | CGAS, TDP1, IAPP | NPBWR1 1696/4885EGFR 4104/4885LATS1 2191/4885 |
| US-20230085472-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH cGAS | CGAS, TDP1, IAPP | NPBWR1 1696/4885EGFR 4104/4885LATS1 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.